Dr. Sulaiman Al Habib Med Group (4013.SE): 2Q26 First Take: Results above GSe/Consensus on better than expected ramp-up of new

Research evidence excerpt

Dr. Sulaiman Al Habib Med Group (4013.SE): 2Q26 First Take: Results above GSe/Consensus on better than expected ramp-up of new

financial statement histories, forecasts and ratios. It can be used for

in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

The rating(s) for Dr. Sulaiman Al Habib Med Group is/are relative to the other companies in its/their coverage universe: AFG International,

Abdullah Al Othaim Markets Co., Air Arabia, Alamar Foods, Aldar Properties, Almarai Co., Americana Restaurants, BinDawood Holding, Cenomi Centers,

Dallah Healthcare Holding, Dar Al Arkan Real Estate, Dr. Sulaiman Al Habib Med Group, Emaar Development, Emaar Properties, Flynas Co, Herfy, Jahez

International, Jarir Marketing Co., Life Healthcare Group, Lulu Retail Holdings, Mouwasat Medical Services, Netcare Ltd., Savola Group, TECOM Group,

Talabat Holding, United Electronics Co.(Extra)

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, “Goldman Sachs”) and companies covered

by Goldman Sachs Global Investment Research and referred to in this research.

There are no company-specific disclosures for: Dr. Sulaiman Al Habib Med Group (SR215.10)

Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

Rating Distribution Investment Banking Relationships

Buy Hold Sell Buy Hold Sell

Global 50% 34% 16% 65% 59% 43%

As of July 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,104 equity securities. Goldman Sachs assigns stocks as Buys

and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral.